Capricor amends 8-K: officer exculpation proposal did not pass, correcting prior report

CAPRICOR THERAPEUTICS, INC.

Proposal 4 (officer exculpation amendment) failed: 5,037,656 for, 1,816,404 against, 103,335 abstain, 9,390,464 broker non-votes.
All other proposals passed: directors elected, auditor ratified, executive compensation approved.
Original 8-K incorrectly reported Proposal 4 as passing; this amendment corrects the vote outcome.
Annual meeting held June 12, 2023; 16,347,859 shares voted of 25,269,926 entitled.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of seven nominees to the Board of Directors at the 2023-06-12 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

1. Each of Dr. Litvack, Dr. Marbán, Ms. Es Sabar, and Messrs. Musket, Dunbar, Manzo, and Collier were elected as directors of the Company to serve until the 2024 annual meeting of stockholders, and until his or her successor is elected, or until his or her earlier death, resignation or removal, as follows: FOR WITHHELD BROKER NON-VOTES Frank Litvack, M.D. 5,848,468 1,108,927 9,390,464 Linda Marbán, Ph.D. 5,897,612 1,059,784 9,390,463 David B. Musket 4,907,731 2,049,664 9,390,464 George W. Dunbar, Jr. 5,838,850 1,118,545 9,390,464 Louis Manzo 5,887,307 1,070,088 9,390,464 Earl M. (Duke) Collier, Jr. 5,439,575 1,517,820 9,390,464 Karimah Es Sabar 5,899,808 1,057,588 9,390,463

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

CAPRICOR THERAPEUTICS, INC. shareholders rejected Amendment to Certificate of Incorporation regarding officer exculpation at the 2023-06-12 meeting.

Proposal: charter amendment
Outcome: failed
Meeting: 2023-06-12

Exact text from the filing

4. The Company’s stockholders did not approve an amendment to the Certificate of Incorporation regarding officer exculpation. The votes were cast as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 5,037,656 1,816,404 103,335 9,390,464

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

CAPRICOR THERAPEUTICS, INC. shareholders approved Ratification of appointment of Rose, Snyder & Jacobs LLP as independent registered public accounting firm at the 2023-06-12 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

2. The appointment by the Audit Committee of the Company’s Board of Directors of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 14,556,113 448,170 1,343,576 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 1.0

CAPRICOR THERAPEUTICS, INC. shareholders approved Advisory vote to approve named executive officer compensation at the 2023-06-12 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

3. The compensation of the Company’s named executive officers was approved, on a non-binding advisory basis, as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 4,328,964 2,446,891 181,541 9,390,463

View on SEC.gov

1184 shareholder votes filed in the last 30 days. Browse all shareholder votes →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-011151

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.